CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES

Authors

  • M.A. Gafur-Axunov Tashkent Institute of Advanced Medical Studies, Republican Scientific Center of ex- medical care
  • N.G. Dadamyants Tashkent Institute of Advanced Medical Studies, Republican Scientific Center of ex- medical care
  • O.I. Mamurov Tashkent Institute of Advanced Medical Studies, Republican Scientific Center of ex- medical care

Keywords:

cardiotoxicity, anthracycline antibiotics, complications of antitumor therapy, consequences of chemoradiotherapy, anthracycline cardiomyopathy, chronic heart failure, prevention and treatment of cardiotoxicity.

Abstract

The article discusses the development of various complications of the cardiovascular system, including very severe
ones, with the development of a fatal outcome in cancer patients receiving chemo-radiotherapy. It is necessary to
consider the possibility not only for development of acute cardiotoxicity, but various complications from cardiovascular
system after cessation of antitumor treatment. Algorithm of patients preparing for such treatment must include
cardiovascular assessment before the start of drugs, and follow-up during the treatment course. Prevention and treatment
of cardiotoxicity are complicated clinical issues due to irreversible and progressing character of most disorders
of cardiovascular system. An important issue is a close collaboration of cardiologist and oncologist in patient’s management.
It is necessary to have long-term dynamic follow-up of patients after chemotherapy for maximally early
diagnostics of cardiovascular complications in long-term period after finishing of antitumor treatment.

Downloads

Published

2020-07-08

How to Cite

Gafur-Axunov, M., Dadamyants, N., & Mamurov , O. (2020). CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES. Toshkent Tibbiyot Akademiyasi Axborotnomasi, (1), 31-36. Retrieved from https://journals.tma.uz/index.php/ttaa/article/view/8

Issue

No. 1 (2020): TTAA

Section

Reviews